CLINICAL-APPLICATION OF MONOCLONAL ANTIBODY-DRUG CONJUGATES FOR IMMUNOTARGETING CHEMOTHERAPY OF COLORECTAL-CARCINOMA

被引：0
|
作者：
TAKAHASHI, T
YAMAGUCHI, T
KITAMURA, K
SUZUYAMA, H
HONDA, M
YOKOTA, T
KOTANAGI, H
TAKAHASHI, M
HASHIMOTO, Y
机构：
[1] AKITA UNIV,DEPT SURG,AKITA 010,JAPAN
[2] TOHOKU UNIV,INST PHARMACEUT,SENDAI,MIYAGI 980,JAPAN
来源：
CANCER | 1988年 / 61卷 / 05期
关键词：
D O I：
10.1002/1097-0142(19880301)61:5<881::AID-CNCR2820610505>3.0.CO;2-Y
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
引用
收藏
页码：881 / 888
页数：8
相关论文
共 50 条
  • [41] Preclinical and clinical pharmacokinetic/pharmacodynamic considerations for antibody-drug conjugates
    Sapra, Puja
    Betts, Alison
    Boni, Joseph
    EXPERT REVIEW OF CLINICAL PHARMACOLOGY, 2013, 6 (05) : 541 - 555
  • [42] Antibody-Drug Conjugates for Cancer Therapy: Chemistry to Clinical Implications
    Dan, Nirnoy
    Setua, Saini
    Kashyap, Vivek K.
    Khan, Sheema
    Jaggi, Meena
    Yallapu, Murali M.
    Chauhan, Subhash C.
    PHARMACEUTICALS, 2018, 11 (02)
  • [43] Clinical perspective: Antibody-drug conjugates for the treatment of breast cancer
    Najminejad, Zohreh
    Dehghani, Fatemeh
    Mirzaei, Yousef
    Mer, Ali Hussein
    Saghi, Seyyed Amirreza
    Abdolvahab, Mohadeseh Haji
    Bagheri, Nader
    Meyfour, Anna
    Jafari, Ameneh
    Jahandideh, Saeed
    Gharibi, Tohid
    Amirkhani, Zahra
    Delam, Hamed
    Mashatan, Noushin
    Shahsavarani, Hosein
    Abdollahpour-Alitappeh, Meghdad
    MOLECULAR THERAPY, 2023, 31 (07) : 1874 - 1903
  • [44] The clinical development of antibody-drug conjugates - lessons from leukaemia
    Jabbour, Elias
    Paul, Shilpa
    Kantarjian, Hagop
    NATURE REVIEWS CLINICAL ONCOLOGY, 2021, 18 (07) : 418 - 433
  • [45] Uncovering therapeutic opportunities in the clinical development of antibody-drug conjugates
    Nieto-Jimenez, Cristina
    Sanvicente, Adrian
    Diaz-Tejeiro, Cristina
    Moreno, Victor
    Lopez de Sa, Alfonso
    Calvo, Emiliano
    Martinez-Lopez, Joaquin
    Perez-Segura, Pedro
    Ocana, Alberto
    CLINICAL AND TRANSLATIONAL MEDICINE, 2023, 13 (09):
  • [46] Clinical strategies with antibody-drug conjugates as potential modifications for virotherapy
    Liao, Zi-Xian
    Huang, Po-Hsiang
    Hsu, Shan-hui
    Chang, Hsiung-Hao
    Chang, Chi-Heng
    Tseng, S. -Ja
    DRUG DISCOVERY TODAY, 2024, 29 (11)
  • [47] Antibody-drug conjugates in cancer therapy: mechanisms and clinical studies
    He, Jun
    Zeng, Xianghua
    Wang, Chunmei
    Wang, Enwen
    Li, Yongsheng
    MEDCOMM, 2024, 5 (08):
  • [48] Monoclonal Antibodies and Antibody-drug Conjugates as Emerging Therapeutics for Breast Cancer Treatment
    Saini, Swati
    Gulati, Nisha
    Awasthi, Rajendra
    Arora, Vimal
    Singh, Sachin Kumar
    Kumar, Shobhit
    Gupta, Gaurav
    Dua, Kamal
    Pahwa, Rakesh
    Dureja, Harish
    CURRENT DRUG DELIVERY, 2024, 21 (07) : 993 - 1009
  • [49] Theranostic antibody-drug conjugates for potential dual application in targeted therapy and fluorescence imaging of colorectal cancer
    Ren, Siyuan
    Sun, Xiang
    Xu, Hua
    Trung Hai Nguyen
    Kang, Chi Soo
    Sadeghipour, Negar
    Xu, Xiaochun
    Wu, Ningjie
    Chen, Yu
    Tichauer, Kenneth
    Minh, David
    Hyun Chong
    ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY, 2018, 256
  • [50] Strategies to address drug interaction potential for antibody-drug conjugates in clinical development
    Lu, Dan
    Sahasranaman, Srikumar
    Zhang, Yi
    Girish, Sandhya
    BIOANALYSIS, 2013, 5 (09) : 1115 - 1130
12345